Page last updated: 2024-11-10

rottlerin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1); [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Mallotusgenus[no description available]EuphorbiaceaeThe spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]

Cross-References

ID SourceID
PubMed CID5281847
CHEMBL ID34241
CHEBI ID8899
CHEBI ID92065
SCHEMBL ID148175
SCHEMBL ID1537089
MeSH IDM0227489

Synonyms (93)

Synonym
einecs 201-395-4
kamalin
acetophenone, 3'-((8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)methyl)-2',4',6'-trihydroxy-5'-methyl-
(e)-1-(6-((3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2h-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one
nsc 94525
brn 0070757
nsc 56346
BRD-K03816923-001-03-9
BRD-K39256324-001-01-5
gtpl2611
EU-0101052
nsc-56346
nsc56346
BIOMOLKI_000058
BSPBIO_001080
LOPAC0_001052
nsc94525
nsc-94525
IDI1_002135
rottlerin
82-08-6
1-[6-(3-acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2h-chromen-8-yl]-3-phenyl-propenone
1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
NCGC00025228-06
mallotoxin
NCGC00025228-05
BIOMOLKI2_000064
BCBCMAP01_000019
NCGC00025228-07
NCGC00025228-02
NCGC00025228-03
NCGC00025228-04
LMPK12120428
R 5648 ,
HMS1990F21
NCGC00025228-08
chebi:8899 ,
CHEMBL34241 ,
1-(6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2h-chromen-8-yl)-3-phenylprop-2-en-1-one
(e)-1-(6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2h-chromen-8-yl)-3-phenylprop-2-en-1-one
bdbm50126829
r5648 (rottlerin)
BMK1-F10 ,
HMS1362F21
HMS1792F21
NCGC00025228-10
NCGC00025228-11
NCGC00025228-09
HMS3263C06
(e)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
smr000058242
MLS003370622
3'-((8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)methyl)-2',4',6'-trihydroxy-5'-methyl-acetophenone
(2e)-1-[6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2h-chromen-8-yl]-3-phenylprop-2-en-1-one
CCG-36482
(e)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methyl-phenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-chromen-8-yl]-3-phenyl-prop-2-en-1-one
(e)-1-[6-[(3-acetyl-2,4,6-trihydroxy-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2h-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one
e29lp3zmuh ,
5-18-05-00695 (beilstein handbook reference)
unii-e29lp3zmuh
LP01052
5,7-dihydroxy-2,2-dimethyl-6-(2,4,6-trihydroxy-3-methyl-5-acetylbenzyl)-8-cinnamoyl-1,2-chromene
rottlerin [mi]
(2e)-1-(6-(3-acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5,7-dihydroxy-2,2-dimethyl-2h-chromen-8-yl)-3-phenylprop-2-en-1-one
SCHEMBL148175
NCGC00261737-01
tox21_501052
DTXSID30231502
SCHEMBL1537089
3'-[(8-cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)methyl]-2',4',6'-trihydroxy-5'-methylacetophenone
AKOS024282482
HB0561
HMS3403F21
mfcd00017361
CHEBI:92065
SR-01000076106-3
SR-01000076106-6
sr-01000076106
SR-01000076106-2
CS-0014823
HY-18980
1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one
rottlerin - cas 82-08-6
NCGC00025228-12
Q7370686
mallotoxin; nsc 56346; nsc 94525
SDCCGSBI-0051022.P002
NCGC00025228-19
MS-29589
S7862
nsc 94525mallotoxin
Z2583131081
F88130

Research Excerpts

Overview

Rottlerin is a natural product consisting of chalcone and flavonoid scaffolds, both of which have previously shown quorum sensing (QS) inhibition in various bacteria. It is an active molecule isolated from Mallotus philippinensis, a medicinal plant used in Ayurvedic Medicine for anti-allergic and anti-helminthic treatments.

ExcerptReferenceRelevance
"Rottlerin (1) is a potent protein kinase C δ inhibitor that possesses a wide range of biological activities. "( The Mosaic of Rottlerin: The Sequel.
Ball, GE; Bhadbhade, M; Black, DS; Ho, KKK; Hong, KKC; Kumar, N, 2019
)
2.32
"Rottlerin is a cytostatic and cytotoxic drug in a variety of cancer cells. "( Multiple mechanisms of Rottlerin toxicity in A375 melanoma cells.
Benincasa, L; Cresti, L; Ietta, F; Maioli, E; Pecorelli, A; Valacchi, G, 2019
)
2.27
"Rottlerin is a natural product consisting of chalcone and flavonoid scaffolds, both of which have previously shown quorum sensing (QS) inhibition in various bacteria. "( Natural Product Rottlerin Derivatives Targeting Quorum Sensing.
Black, DS; Das, T; Kumar, N; Sabir, S; Suresh, D; Wenholz, D; Yu, TT, 2021
)
2.41
"Rottlerin is a natural polyphenolic compound that was initially indicated as a PKCδ inhibitor. "( Rottlerin as a therapeutic approach in psoriasis: Evidence from in vitro and in vivo studies.
Cai, SQ; Chen, JQ; Landeck, L; Li, W; Man, XY; Min, M; Wang, P; Yan, BX; Zheng, M, 2017
)
3.34
"Rottlerin is an active molecule isolated from Mallotus philippinensis, a medicinal plant used in Ayurvedic Medicine System for anti-allergic and anti-helminthic treatments."( Anti-allergic actions of rottlerin from Mallotus philippinensis in experimental mast cell-mediated anaphylactic models.
Chan, TK; Cheng, C; Guan, SP; Koh, HM; Ng, DS; Wong, WS, 2013
)
1.41
"Rottlerin (Rott) is an active molecule isolated from Mallotus philippinensis, a medicinal plant used in Ayurvedic Medicine for anti-allergic and anti-helminthic treatments, demonstrates anticancer activities."( Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway.
Kumar, D; Shankar, S; Srivastava, RK, 2014
)
2.57
"Rottlerin was shown to be a specific inhibitor of transfection by polyethylene imine (PEI-25)/DNA complexes, leading to a decrease in the amount of transfected HeLa and CHO-K1 cells and a decrease in the expression of enhanced green fluorescent protein (EGFP) reporter gene by up to 50%."( Fluid phase endocytosis contributes to transfection of DNA by PEI-25.
Hakim, P; Hollfelder, F; Hufnagel, H; Lima, A, 2009
)
1.07
"Rottlerin is a polyphenolic compound derived from Mallotus philipinensis. "( Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family.
Abrol, R; Damoiseaux, RD; Edderkaoui, M; Eibl, G; Goddard, WA; Gukovskaya, AS; Odinokova, I; Ohno, I; Pandol, SJ; Yazbec, M; Yokosuka, O, 2010
)
3.25
"Rottlerin is a natural polyphenolic compound, which was initially indicated and marketed as a PKC delta inhibitor and recently proposed and patented as an anti-hypertensive drug. "( Rottlerin: bases for a possible usage in psoriasis.
Maioli, E; Valacchi, G, 2010
)
3.25
"Rottlerin is a widely selective protein kinase C delta (PKCdelta) inhibitor isolated from Mallotus philippinensis. "( The PKC delta inhibitor, rottlerin, induces apoptosis of haematopoietic cell lines through mitochondrial membrane depolarization and caspases' cascade.
Chang, WH; Hour, TC; Hung, HC; Hung, YC; Liao, YF; Liu, GY; Tsay, GJ, 2005
)
2.07
"Rottlerin was found to be an excellent tool for FPE analysis: rapid-acting, irreversible and selective for FPE (as opposed to receptor-mediated endocytosis) at concentrations of 3 microM and below."( Selective inhibition by rottlerin of macropinocytosis in monocyte-derived dendritic cells.
Erlandsen, SL; Kruhlak, MJ; Sarkar, K; Shaw, S, 2005
)
1.36
"Rottlerin is a pharmacological inhibitor of protein kinase C (PKC) theta, a novel PKC selectively expressed in T lymphocytes. "( Rottlerin inhibits human T cell responses.
Goldman, M; Rahmouni, S; Springael, C; Thomas, S; Vandamme, A; Vosters, O; Willems, F, 2007
)
3.23

Effects

Rottlerin has been reported to exert its anti-tumor activity in various types of human cancers. The compound has been shown to induce antiproliferation and apoptosis of human cancer cell lines.

ExcerptReferenceRelevance
"Rottlerin has been reported to exert its anti-tumor activity in various types of human cancers. "( Rottlerin upregulates DDX3 expression in hepatocellular carcinoma.
Gao, QG; Li, B; Shen, GH; Wang, Z; Xie, JM, 2018
)
3.37
"Rottlerin has recently been identified as a potent BKCa activator."( Rottlerin-induced BKCa channel activation impairs specific contractile responses and promotes vasodilation.
Clements, RT; Cordeiro, B; Sellke, FW; Shinn, C, 2015
)
2.58
"Rottlerin (mallotoxin) has been implicated as a potent BKCa activator."( BKCa channel activation increases cardiac contractile recovery following hypothermic ischemia/reperfusion.
Clements, RT; Cordeiro, B; Terentyev, D, 2015
)
1.14
"Rottlerin has been shown to induce antiproliferation and apoptosis of human cancer cell lines. "( Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells.
Choi, KS; Kwon, TK; Lim, JH; Park, JW; Park, YB, 2009
)
3.24
"Rottlerin has been reported to inhibit apoptosis in many cell types, possibly through direct or indirect effects on PKCdelta."( Effects of rottlerin on silica-exacerbated systemic autoimmune disease in New Zealand mixed mice.
Brown, JM; Holian, A; Pershouse, MA; Pfau, JC; Schwanke, CM, 2005
)
1.44
"Rottlerin has been used as a protein kinase Cdelta (PKCdelta)-selective inhibitor in hundreds of studies, on the basis of initial substrate phosphorylation studies in vitro. "( Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta.
Soltoff, SP, 2007
)
3.23
"Rottlerin has been widely accepted as a specific inhibitor of protein kinase C delta (PKC delta); however, recent data suggest that the specificity of this compound become a question. "( Rottlerin induces calcium influx and protein degradation in cultured lenses independent of effects on protein kinase C delta.
Xu, SZ, 2007
)
3.23

Actions

Rottlerin was found to inhibit IgE-induced PLCγ1 and Akt phosphorylation, production of IP3 and rise in cytosolic Ca²⁺ level in mast cells. It significantly reduced the hypertrophic effect of DHT and PMA on NRCMs and H9c2 cells.

ExcerptReferenceRelevance
"Rottlerin, that may inhibit PKCδ, significantly reduced the hypertrophic effect of DHT and PMA on NRCMs and H9c2 cells."( Prenatal exposure to testosterone induces cardiac hypertrophy in adult female rats through enhanced Pkcδ expression in cardiac myocytes.
Gu, HC; Hou, M; Huang, HF; Jiang, ZR; Lin, J; Liu, XM; Sheng, JZ; Wang, HH; Wu, YM; Wu, YT; Yang, Q; Zhou, CL, 2019
)
1.24
"Rottlerin was found to inhibit IgE-induced PLCγ1 and Akt phosphorylation, production of IP3 and rise in cytosolic Ca²⁺ level in mast cells."( Anti-allergic actions of rottlerin from Mallotus philippinensis in experimental mast cell-mediated anaphylactic models.
Chan, TK; Cheng, C; Guan, SP; Koh, HM; Ng, DS; Wong, WS, 2013
)
1.41

Treatment

Pretreatment with rottlerin (6 microM) did not enhance the cardioprotective effects of FR-167653 (2.2 microM). Rottlerin treatment in primary mesencephalic cultures significantly attenuated MPP(+)-induced tyrosine hydroxylase (TH)-positive neuronal cell and neurite loss.

ExcerptReferenceRelevance
"Rottlerin-treated mice showed a significant inhibition in tumor growth which was associated with suppression of cell proliferation, activation of capase-3 and cleavage of PARP."( Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang, M; Jackman, CP; Marsh, JL; Shankar, S; Srivastava, RK; Tang, SN; Upadhyay, G, 2014
)
2.57
"Rottlerin treatment also resulted in a marked reduction in the migration of CGTH W-2 cells."( Rottlerin inhibits migration of follicular thyroid carcinoma cells by PKCdelta-independent destabilization of the focal adhesion complex.
Chen, Y; Huang, SH; Lin, CJ; Lin, CY; Wang, SM, 2010
)
2.52
"Rottlerin pretreatment also attenuated LPS-induced phosphorylation of IkappaB-alpha, nuclear translocation of NF-kappaB, and expression of type II nitric oxide synthase."( Effect of rottlerin, a PKC-delta inhibitor, on TLR-4-dependent activation of murine microglia.
Baek, NI; Jeong, MW; Kim, DC; Kim, KT; Kim, SH, 2005
)
1.45
"Rottlerin treatment in primary mesencephalic cultures significantly attenuated MPP(+)-induced tyrosine hydroxylase (TH)-positive neuronal cell and neurite loss."( Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
Anantharam, V; Kanthasamy, A; Kanthasamy, AG; Zhang, D, 2007
)
1.3
"Rottlerin treatment induced a dose- and time-dependent inhibition of cell growth, and cytoplasmic vacuolations were markedly shown."( Rottlerin induces autophagy and apoptotic cell death through a PKC-delta-independent pathway in HT1080 human fibrosarcoma cells: the protective role of autophagy in apoptosis.
Hwang, BD; Jung, YJ; Kim, JS; Kim, YR; Kweon, GR; Lim, K; Park, JH; Park, JI; Seo, KS; Song, KS; Yoon, WH; Yun, EJ, 2008
)
2.51
"Rottlerin-treated HaCaT cells proliferated like transformed cells in a three-dimensional cell culture system."( Rottlerin induces a transformed phenotype in human keratinocytes.
Borchert-Stuhlträger, M; Dietrich, C; Gumpert, N; Heit, I; Oesch, F; Wieser, R, 2001
)
2.47
"The treatment of rottlerin led to disrupting the PRRSV entry pathway by blocking endocytosis of the virions."( Inhibition of endocytosis of porcine reproductive and respiratory syndrome virus by rottlerin and its potential prophylactic administration in piglets.
Ahn, SH; Choi, HY; Choi, IS; Choi, JC; Kang, YL; Lee, JB; Lee, SW; Oh, C; Park, SY; Song, CS, 2021
)
1.17
"Treatment with rottlerin, a PKCδ inhibitor, decreased Iba-1 and C3 expression, but did not affect S100A10 expression, suggesting that PKCδ inhibition attenuates microglial activation and A1 astrocyte phenotype polarization."( Effect of rottlerin on astrocyte phenotype polarization after trimethyltin insult in the dentate gyrus of mice.
Hwang, Y; Kim, HC; Shin, EJ, 2022
)
1.46
"Treatment with rottlerin or ASO significantly attenuated the MA-induced increase in protein phosphatase (PP) 2A activity."( Inhibition of protein kinase (PK) Cδ attenuates methamphetamine-induced dopaminergic toxicity via upregulation of phosphorylation of tyrosine hydroxylase at Ser40 by modulation of protein phosphatase 2A and PKA.
Dang, DK; Duong, CX; Jang, CG; Jeong, JH; Kim, HC; Lim, YK; Nabeshima, T; Nah, SY; Nam, Y; Shin, EJ, 2015
)
0.76
"Pretreatment with rottlerin caused depressed U46619 responses, but had no effect on PE, SNP, or H2S-mediated responses."( Rottlerin-induced BKCa channel activation impairs specific contractile responses and promotes vasodilation.
Clements, RT; Cordeiro, B; Sellke, FW; Shinn, C, 2015
)
2.18
"Pretreatment with rottlerin (6 microM) did not enhance the cardioprotective effects of FR-167653 (2.2 microM)."( Possible mechanism of rottlerin induced modulation of ischemia reperfusion injury in isolated rat hearts.
Jaggi, AS; Kaur, K; Singh, M; Singh, N, 2008
)
0.98
"Treatment with rottlerin (10 microM), a selective inhibitor of PKC-delta did not affect the cardioprotective effects of IPC in normal rat hearts; but its treatment significantly restored the cardioprotective potentials of IPC in hyperhomocysteinemic rat hearts."( Possible involvement of PKC-delta in the abrogated cardioprotective potential of ischemic preconditioning in hyperhomocysteinemic rat hearts.
Bala kumar, P; Rohilla, A; Singh, G; Singh, M, 2010
)
0.7
"Treatment with rottlerin (10 microM), a selective inhibitor of PKC-delta, did not affect the cardioprotective effect of IPOC in normal rat hearts; but its treatment significantly restored the myocardial infarct size-limiting effect of IPOC in Hhcy rat hearts."( The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocysteinemic (Hhcy) rat hearts: the reasonable role of PKC-delta.
Balakumar, P; Rohilla, A, 2009
)
0.69
"Treatment with rottlerin 1 μmol/L significantly improved CP-induced cardiac function (left ventricular diastolic pressure, 20 ± 5.9%; ± dP/dt, 5.2 ± 4.5%, -11.6 ± 4.7% decrease versus baseline; P<0.05 CP+R versus CP)."( Rottlerin increases cardiac contractile performance and coronary perfusion through BKCa++ channel activation after cold cardioplegic arrest in isolated hearts.
Bianchi, C; Clements, RT; Cordeiro, B; Feng, J; Sellke, FW, 2011
)
2.15
"Treatment with rottlerin enhanced IL-1β-induced COX-2 expression at both the protein and mRNA levels."( Rottlerin enhances IL-1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells.
Kwon, TK; Park, EJ, 2011
)
2.15
"Treatment with rottlerin significantly decreased Cdc2 activity through the downregulation of cyclin A, cyclin B, and Cdc2 proteins, whereas the sensitizing effect of rottlerin on TRAIL-induced apoptosis was independent of PKCdelta activity."( Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Choi, KS; Kim, EH; Kim, SU, 2005
)
2.11
"Pretreatment with rottlerin and Bis alone did not influence the survival of the cells significantly,."( [Phosphorylation of PKCdelta participates in the toxicity of 6-hydroxydopamine on dopaminergic neuroblastoma cell].
Fan, Y; Li, HL; Li, ZW; Teng, ZY; Wu, XW; Zhang, YN; Zhang, YQ, 2006
)
0.66
"Treatment with Rottlerin, a specific PKCdelta inhibitor, significantly inhibited drug-induced Cer formation and apoptosis in LNCaP cells, as did overexpression of dominant negative-type PKCdelta."( Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.
Asakuma, J; Asano, T; Hayakawa, M; Kuroki, T; Ohba, M; Sumitomo, M, 2002
)
0.65

Toxicity

ExcerptReferenceRelevance
" Human RPE cell line RPE50 and ARPE19 cells were pretreated with specific inhibitors or transfected with shRNAs of various PKC isozymes, including PKCα, β, ε, γ, and δ, to examine whether EMB-induced toxic effects were prevented."( PKCδ-dependent signaling mediates ethambutol-induced toxic effects on human retinal pigment cells.
Chen, ZY; He, MS; Tsai, RK; Wu, WC; Wu, WS, 2011
)
0.37
" In contrast, pretreatment of the cells with specific inhibitors of PKCα, β, ε, or γ, or depletion of PKCα or β didn't influence the aforementioned EMB-triggered toxic effects."( PKCδ-dependent signaling mediates ethambutol-induced toxic effects on human retinal pigment cells.
Chen, ZY; He, MS; Tsai, RK; Wu, WC; Wu, WS, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, we established a melanogenesis regulation assay system using a fluorescent protein reporter combined with the promoters for the microphthalmia-associated transcription factor (MITF), tyrosinase (Tyr) and dopachrome tautomerase (Dct) genes in MeWo human melanoma cells."( Establishment of a melanogenesis regulation assay system using a fluorescent protein reporter combined with the promoters for the melanogenesis-related genes in human melanoma cells.
Chen, CY; Chiu, YW; Lin, CC; Lin, YJ; Yang, CH, 2015
)
0.42
" Therefore, we hypothesized the improved anticancer efficacy of QUE in combination with isoenzyme inhibitors-rottlerin (ROT-PKCδ inhibitor), G0 6983 (PKCα inhibitor), and PI-103 (p110α-class I PI3K inhibitor) in MCF-7 and RAW 264."( Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
Maurya, AK; Vinayak, M, 2019
)
0.95

Bioavailability

ExcerptReferenceRelevance
"Cyclodextrins are widely used excipients for increasing the bioavailability of poorly water-soluble drugs."( Fluorescently labeled methyl-beta-cyclodextrin enters intestinal epithelial Caco-2 cells by fluid-phase endocytosis.
Bácskay, I; Bacsó, Z; Fehér, P; Fenyvesi, É; Fenyvesi, F; Gutay-Tóth, Z; Malanga, M; Réti-Nagy, K; Szabó, G; Szente, L; Ujhelyi, Z; Váradi, J; Vecsernyés, M, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A requirement for PKC betaII for phagocytosis was demonstrated collectively by phorbol 12-myristate 13-acetate-induced depletion of PKC betaII, by dose-response to PKC inhibitor Ro-32-0432, and by use of PKC betaII myristoylated peptide as a blocker."( Activation of protein kinase C beta II by the stereo-specific phosphatidylserine receptor is required for phagocytosis of apoptotic thymocytes by resident murine tissue macrophages.
Curtis, JL; Hu, B; Polak, T; Punturieri, A; Sonstein, J; Todt, JC, 2002
)
0.31
"Many screening hits inhibit enzymes with steep dose-response curves, which are considered pathological."( Interpreting steep dose-response curves in early inhibitor discovery.
Shoichet, BK, 2006
)
0.33
" Dose-response experiments in primary cells confirmed pathway selectivity, but importantly also revealed differential inhibition of cell types and new druggability trends across multiple compounds."( High-content single-cell drug screening with phosphospecific flow cytometry.
Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP, 2008
)
0.35
" Both groups were subdivided into the three groups and administered with 0, 5 or 50 mg CPZ per kg body weight (control, low dosage of chlorpromazine (LCPZ), high dosage chlorpromazine (HCPZ)) for 8 weeks."( Chlorpromazine attenuates pancreatic beta-cell function and mass through IRS2 degradation, while exercise partially reverses the attenuation.
Hong, SM; Kim, SH; Lee, JE; Park, S; Sung, SR, 2008
)
0.35
" Cholecystokinin-8 stimulation induced a typical biphasic dose-response curve for amylase secretion in acinar cells isolated from both PKC delta(-/-) and wild type mice, with maximal stimulation at 10-pmol/L CCK."( Protein kinase C delta-mediated processes in cholecystokinin-8-stimulated pancreatic acini.
Cheriyan, S; Gorelick, FS; Kolodecik, TR; Lugea, A; Pandol, SJ; Reeve, JR; Thrower, EC; Wang, J; Yuan, J, 2009
)
0.35
" Despite unobvious contributions of known signaling pathways in dose-response mediation, microarray analysis identified transcriptional expression of UVB-response genes related to the respiratory-chain."( Unexpected dose response of HaCaT to UVB irradiation.
Chang, CT; Chang, RS; Chen, CS; Chiang, CS; Chuang, CY; Chung, WJ; Cui, Y; Hsu, IC; Huang, CL; Shu, WY, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
K-ATP channel agonistA compound which acts as an agonist at the ATP-sensitive K+ channel.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
anti-allergic agentA drug used to treat allergic reactions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
chromenolAny chromene carrying one or more hydroxy substituents.
benzenetriolA triol in which three hydroxy groups are substituted onto a benzene ring.
methyl ketoneA ketone of formula RC(=O)CH3 (R =/= H).
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.18380.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency23.17690.004023.8416100.0000AID485290
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency32.46480.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency32.76520.125919.1169125.8920AID2353; AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency25.44015.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency21.71230.002014.677939.8107AID1476; AID1478
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.10270.100020.879379.4328AID488773; AID588453
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID493107
Fumarate hydrataseHomo sapiens (human)Potency19.95260.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency59.16890.031637.5844354.8130AID504865; AID540327
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency19.33870.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency16.72380.180013.557439.8107AID1460; AID1468
DNA polymerase III, partialBacillus subtilisPotency18.88761.062114.152826.6795AID485295
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency24.20950.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency24.15350.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency12.58930.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.37810.001530.607315,848.9004AID1224819; AID1224820; AID1224821
polyproteinZika virusPotency19.95260.00308.794948.0869AID1347053
IDH1Homo sapiens (human)Potency15.84890.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.12380.035520.977089.1251AID504332
serine-protein kinase ATM isoform aHomo sapiens (human)Potency16.39740.707925.111941.2351AID504362; AID504366
Bloom syndrome protein isoform 1Homo sapiens (human)Potency31.62280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency47.754823.934123.934123.9341AID1967
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency25.66480.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency12.58930.006026.168889.1251AID488953
DNA polymerase betaHomo sapiens (human)Potency22.38720.022421.010289.1251AID485314
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency53.05620.133725.412989.1251AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.93300.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency25.11890.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency44.96470.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency3.28700.004611.374133.4983AID463097; AID504364
DNA polymerase kappa isoform 1Homo sapiens (human)Potency34.41170.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency14.13100.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency31.77800.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency13.29570.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency10.43040.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency1.00000.015812.3113615.5000AID1461
Ataxin-2Homo sapiens (human)Potency25.11890.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Eukaryotic elongation factor 2 kinaseHomo sapiens (human)IC50 (µMol)5.30000.06001.03865.3000AID1703947
B2 bradykinin receptorCavia porcellus (domestic guinea pig)IC50 (µMol)1.20000.00112.58648.0000AID43124
Ubiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)IC50 (µMol)8.00002.00005.61258.0000AID1315765
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)119.00000.98004.05607.2000AID1510602; AID1510604
Beta-lactamaseEscherichia coli K-12IC50 (µMol)25.00000.01502.46578.0000AID275970; AID275971; AID275973; AID43124
Beta-lactamaseEnterobacter cloacaeIC50 (µMol)119.00000.10001.87457.7000AID1510602; AID1510604
Malate dehydrogenaseThermus thermophilusIC50 (µMol)0.70000.70004.90008.0000AID106657
Protein kinase C alpha typeHomo sapiens (human)IC50 (µMol)20.00000.00010.972010.0000AID1799534
Chymotrypsinogen BHomo sapiens (human)IC50 (µMol)25.000010.000010.000010.0000AID52462
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)1.20000.00031.38338.4000AID43124
Protein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)IC50 (µMol)20.00000.04502.67428.0000AID1799534
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)20.00000.02204.20249.4000AID1799534
MAP kinase-activated protein kinase 2Homo sapiens (human)IC50 (µMol)5.40000.00201.16206.0000AID512461
Tyrosine-protein kinase JAK3Homo sapiens (human)IC50 (µMol)20.00000.00010.41937.9200AID1799534
Protein kinase C delta typeHomo sapiens (human)IC50 (µMol)3.00000.00010.844810.0000AID163518; AID1902441
Receptor-type tyrosine-protein phosphatase etaHomo sapiens (human)IC50 (µMol)20.00001.00002.00003.0000AID1799534
Receptor protein-tyrosine kinase Homo sapiens (human)IC50 (µMol)20.00000.04302.37495.9500AID1799534
MAP kinase-activated protein kinase 5Homo sapiens (human)IC50 (µMol)1.90000.00501.15753.0100AID127098; AID512460
WD repeat-containing protein 48Homo sapiens (human)IC50 (µMol)8.00002.00006.31678.0000AID1315765
RuvB-like 1Homo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID1891067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (246)

Processvia Protein(s)Taxonomy
response to ischemiaEukaryotic elongation factor 2 kinaseHomo sapiens (human)
translational elongationEukaryotic elongation factor 2 kinaseHomo sapiens (human)
regulation of protein autophosphorylationEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cellular response to insulin stimulusEukaryotic elongation factor 2 kinaseHomo sapiens (human)
negative regulation of apoptotic processEukaryotic elongation factor 2 kinaseHomo sapiens (human)
positive regulation of endocytosisEukaryotic elongation factor 2 kinaseHomo sapiens (human)
protein autophosphorylationEukaryotic elongation factor 2 kinaseHomo sapiens (human)
positive regulation of synapse assemblyEukaryotic elongation factor 2 kinaseHomo sapiens (human)
positive regulation of dendritic spine morphogenesisEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cellular response to calcium ionEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cellular response to cAMPEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cellular response to anoxiaEukaryotic elongation factor 2 kinaseHomo sapiens (human)
regulation of translation at postsynapseEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusEukaryotic elongation factor 2 kinaseHomo sapiens (human)
response to prolactinEukaryotic elongation factor 2 kinaseHomo sapiens (human)
myosin II filament disassemblyEukaryotic elongation factor 2 kinaseHomo sapiens (human)
skeletal system developmentUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
DNA repairUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
regulation of DNA repairUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
response to UVUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
positive regulation of error-prone translesion synthesisUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
digestionChymotrypsinogen ABos taurus (cattle)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
digestionChymotrypsinogen BHomo sapiens (human)
proteolysisChymotrypsinogen BHomo sapiens (human)
gene expressionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
dopamine secretionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatin remodelingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
proteolysisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide cross-linkingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein deaminationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of GTPase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of cell adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of neurogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of mitochondrial calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
bone developmentProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
branching involved in salivary gland morphogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
salivary gland cavitationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to cocaineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to dopamineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of sprouting angiogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to serotoninProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
toll-like receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
leukotriene metabolic processMAP kinase-activated protein kinase 2Homo sapiens (human)
inflammatory responseMAP kinase-activated protein kinase 2Homo sapiens (human)
DNA damage responseMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
response to lipopolysaccharideMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of interleukin-6 productionMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
response to cytokineMAP kinase-activated protein kinase 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMAP kinase-activated protein kinase 2Homo sapiens (human)
p38MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of mRNA stabilityMAP kinase-activated protein kinase 2Homo sapiens (human)
macropinocytosisMAP kinase-activated protein kinase 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
inner ear developmentMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionMAP kinase-activated protein kinase 2Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of cellular response to heatMAP kinase-activated protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-activated protein kinase 2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
vasculogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
heart developmentReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
blood coagulationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell population proliferationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of platelet activationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of macrophage chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet formationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell growthReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell migrationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
glucose homeostasisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of vascular permeabilityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of MAP kinase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
oligodendrocyte differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phagocytosisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of calcium-mediated signalingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of focal adhesion assemblyReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
contact inhibitionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of translationMAP kinase-activated protein kinase 5Homo sapiens (human)
signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
Ras protein signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
negative regulation of TOR signalingMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMAP kinase-activated protein kinase 5Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomerase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of dendritic spine developmentMAP kinase-activated protein kinase 5Homo sapiens (human)
cellular senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
stress-induced premature senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of signal transduction by p53 class mediatorMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere cappingMAP kinase-activated protein kinase 5Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
DNA damage responseWD repeat-containing protein 48Homo sapiens (human)
spermatogenesisWD repeat-containing protein 48Homo sapiens (human)
single fertilizationWD repeat-containing protein 48Homo sapiens (human)
multicellular organism growthWD repeat-containing protein 48Homo sapiens (human)
skin developmentWD repeat-containing protein 48Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATWD repeat-containing protein 48Homo sapiens (human)
embryonic organ developmentWD repeat-containing protein 48Homo sapiens (human)
skeletal system morphogenesisWD repeat-containing protein 48Homo sapiens (human)
homeostasis of number of cellsWD repeat-containing protein 48Homo sapiens (human)
positive regulation of epithelial cell proliferationWD repeat-containing protein 48Homo sapiens (human)
seminiferous tubule developmentWD repeat-containing protein 48Homo sapiens (human)
regulation of protein monoubiquitinationWD repeat-containing protein 48Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationWD repeat-containing protein 48Homo sapiens (human)
double-strand break repair via homologous recombinationWD repeat-containing protein 48Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
telomere maintenanceRuvB-like 1Homo sapiens (human)
regulation of DNA replicationRuvB-like 1Homo sapiens (human)
DNA repairRuvB-like 1Homo sapiens (human)
regulation of DNA repairRuvB-like 1Homo sapiens (human)
DNA recombinationRuvB-like 1Homo sapiens (human)
chromatin remodelingRuvB-like 1Homo sapiens (human)
regulation of DNA-templated transcriptionRuvB-like 1Homo sapiens (human)
spermatogenesisRuvB-like 1Homo sapiens (human)
DNA duplex unwindingRuvB-like 1Homo sapiens (human)
regulation of chromosome organizationRuvB-like 1Homo sapiens (human)
regulation of apoptotic processRuvB-like 1Homo sapiens (human)
positive regulation of DNA repairRuvB-like 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionRuvB-like 1Homo sapiens (human)
regulation of embryonic developmentRuvB-like 1Homo sapiens (human)
protein stabilizationRuvB-like 1Homo sapiens (human)
cell divisionRuvB-like 1Homo sapiens (human)
regulation of cell cycleRuvB-like 1Homo sapiens (human)
regulation of DNA strand elongationRuvB-like 1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayRuvB-like 1Homo sapiens (human)
positive regulation of telomere maintenance in response to DNA damageRuvB-like 1Homo sapiens (human)
positive regulation of telomerase RNA localization to Cajal bodyRuvB-like 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationRuvB-like 1Homo sapiens (human)
regulation of double-strand break repairRuvB-like 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIRuvB-like 1Homo sapiens (human)
box C/D snoRNP assemblyRuvB-like 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
protein kinase activityEukaryotic elongation factor 2 kinaseHomo sapiens (human)
elongation factor-2 kinase activityEukaryotic elongation factor 2 kinaseHomo sapiens (human)
calcium ion bindingEukaryotic elongation factor 2 kinaseHomo sapiens (human)
calmodulin bindingEukaryotic elongation factor 2 kinaseHomo sapiens (human)
ATP bindingEukaryotic elongation factor 2 kinaseHomo sapiens (human)
translation factor activity, RNA bindingEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
peptidase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
serine-type endopeptidase activityChymotrypsinogen BHomo sapiens (human)
protein-glutamine gamma-glutamyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
calcium ion bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
GTP bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptidase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein-glutamine glutaminase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone serotonyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone dopaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide noradrenalinyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide histaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
beta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
gamma-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
mitogen-activated protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
delta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
p53 bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
MAP kinase kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
DNA bindingWD repeat-containing protein 48Homo sapiens (human)
double-stranded DNA bindingWD repeat-containing protein 48Homo sapiens (human)
single-stranded DNA bindingWD repeat-containing protein 48Homo sapiens (human)
protein bindingWD repeat-containing protein 48Homo sapiens (human)
deubiquitinase activator activityWD repeat-containing protein 48Homo sapiens (human)
ubiquitin bindingWD repeat-containing protein 48Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
TFIID-class transcription factor complex bindingRuvB-like 1Homo sapiens (human)
DNA helicase activityRuvB-like 1Homo sapiens (human)
transcription coactivator activityRuvB-like 1Homo sapiens (human)
protein bindingRuvB-like 1Homo sapiens (human)
ATP bindingRuvB-like 1Homo sapiens (human)
ATP hydrolysis activityRuvB-like 1Homo sapiens (human)
TBP-class protein bindingRuvB-like 1Homo sapiens (human)
ADP bindingRuvB-like 1Homo sapiens (human)
cadherin bindingRuvB-like 1Homo sapiens (human)
ATPase bindingRuvB-like 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
cytoplasmEukaryotic elongation factor 2 kinaseHomo sapiens (human)
cytosolEukaryotic elongation factor 2 kinaseHomo sapiens (human)
postsynaptic densityEukaryotic elongation factor 2 kinaseHomo sapiens (human)
dendritic spineEukaryotic elongation factor 2 kinaseHomo sapiens (human)
glutamatergic synapseEukaryotic elongation factor 2 kinaseHomo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
extracellular regionChymotrypsinogen BHomo sapiens (human)
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleusProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
endoplasmic reticulumProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cytosolProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
plasma membraneProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
focal adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular exosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatinProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
centrosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 2Homo sapiens (human)
extracellular exosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
immunological synapseReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell-cell junctionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell surfaceReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
ruffle membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 5Homo sapiens (human)
septin cytoskeletonMAP kinase-activated protein kinase 5Homo sapiens (human)
protein-containing complexMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmWD repeat-containing protein 48Homo sapiens (human)
nucleusWD repeat-containing protein 48Homo sapiens (human)
nucleoplasmWD repeat-containing protein 48Homo sapiens (human)
lysosomeWD repeat-containing protein 48Homo sapiens (human)
late endosomeWD repeat-containing protein 48Homo sapiens (human)
cytosolWD repeat-containing protein 48Homo sapiens (human)
intracellular membrane-bounded organelleWD repeat-containing protein 48Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleosomeRuvB-like 1Homo sapiens (human)
nucleusRuvB-like 1Homo sapiens (human)
nucleoplasmRuvB-like 1Homo sapiens (human)
centrosomeRuvB-like 1Homo sapiens (human)
cytosolRuvB-like 1Homo sapiens (human)
membraneRuvB-like 1Homo sapiens (human)
nuclear matrixRuvB-like 1Homo sapiens (human)
Ino80 complexRuvB-like 1Homo sapiens (human)
NuA4 histone acetyltransferase complexRuvB-like 1Homo sapiens (human)
extracellular exosomeRuvB-like 1Homo sapiens (human)
R2TP complexRuvB-like 1Homo sapiens (human)
protein folding chaperone complexRuvB-like 1Homo sapiens (human)
dynein axonemal particleRuvB-like 1Homo sapiens (human)
RPAP3/R2TP/prefoldin-like complexRuvB-like 1Homo sapiens (human)
Swr1 complexRuvB-like 1Homo sapiens (human)
MLL1 complexRuvB-like 1Homo sapiens (human)
ribonucleoprotein complexRuvB-like 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (289)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID417417Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 323-332 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435356Percentage IKK-beta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435745Percentage PLK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1510612Inhibition of Enterobacter cloacae beta-lactamase at 200 uM incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of 1 mM DTT by spectrophotometric analysis relative to control2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID43256Percentage inhibition against beta-Lactamase in the absence of detergent Triton X-100 was determined at a concentration of 5 uM2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID512286Inhibition of bovine heart PKA at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID417408Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 336-350 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435542Percentage PKBbeta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435844Percentage CaMK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID417418Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 336-350 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID417409Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 8-18 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deuter2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771640Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 30 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 54%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417385Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 243-250 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1510607Inhibition of alpha-chymotrypsin in bovine pancreas using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins in presence of Triton X-100 by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1525149Stability of the compound in toluene under room temperature by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID218565Increase in inhibition of beta-lactamase due to the effect of incubation2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID435488Percentage p38beta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436078Percentage DYRK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID43124Inhibitory activity against Amp C beta-Lactamase2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID771655Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID512294Inhibition of rat liver AMPK at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID771651Cytotoxicity against human PC3 cells after 48 hrs by MTT assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435720Percentage ERK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417410Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 42-56 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deute2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771624Induction of apoptosis in human HL60 cells assessed as formation of scattered apoptotic bodies at 20 to 40 uM after 24 hrs by fluorescence microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID274377Inhibition of human recombinant SIRT2 at 12.5 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID512296Inhibition of PHK from rabbit skeletal muscle at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435741Percentage PKCzeta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771627Induction of apoptosis in human HL60 cells assessed as cell wall deformation at 20 to 40 uM after 24 hrs by fluorescence microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417414Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 243-250 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512285Inhibition of His-tagged human PRAK expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID497648Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 30 uM in presence of 5 mg/ml BSA by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID512288Inhibition of His-tagged human PDK1 expressed in Sf21 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID771628Induction of apoptosis in human HL60 cells assessed as vesicle formation at 10 to 40 uM after 24 hrs by phase contrast microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417387Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 291-322 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID43264Percentage inhibition against beta-Lactamase in the presence of detergent 0.01% Triton X-100 was determined at a concentration of 5 uM2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
A specific mechanism of nonspecific inhibition.
AID495064Inhibition of JAK-mediated GM-CSF-induced Stat5 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID435341Percentage CHK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435240Percentage JNK3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771654Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435308Percentage PKCalpha activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512283Inhibition of His-tagged human MAPKAPK2 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435991Percentage SGK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771630Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G0 phase after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435126Percentage p38-gamma activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID497664Inhibition of yeast prion protein Sup35 infection of PSI yeast spheroplast cells at 200 uM2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID417400Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 42-56 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512290Inhibition of His-tagged human SGK expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435824Percentage PKA activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID275973Inhibition of 30 nM AmpC beta lactamase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Interpreting steep dose-response curves in early inhibitor discovery.
AID435850Percentage DYRK3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417392Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 105-128 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435726Percentage JNK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID327792Inhibition of ERK1 phosphorylation in IgE-sensitized rat RBL2H3 cells assessed as histamine release at 100 uM after 30 mins2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Inhibitory effect of xanthones isolated from the pericarp of Garcinia mangostana L. on rat basophilic leukemia RBL-2H3 cell degranulation.
AID435869Percentage p38alpha activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435753Percentage S6K1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512293Inhibition of rat ROCK2 expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID1510602Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID435483Percentage NEK2a activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417401Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 105-128 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1703947Inhibition of eEF2K (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.
AID497656Inhibition of mouse prion protein (89-230) assessed as inhibition of amyloid polymerization at 25 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID435971Percentage MAPKAPK3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1591937Antibacterial activity against Pseudomonas aeruginosa by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID1525142Drug metabolism in DMSO-d6 assessed as isorottlerin formation measured after 2 months at room temperature by RP-HPLC analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID512443Inhibition of His-tagged human PKCdelta expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435368Percentage NEK7 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435968Percentage GSK3-beta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436073Percentage CSK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID106657Inhibitory activity against malate dehydrogenase (MDH) from Thermus flavus2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID327795Inhibition of ERK2 phosphorylation in IgE-sensitized rat RBL2H3 cells assessed as histamine release at 2 uM after 30 mins2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Inhibitory effect of xanthones isolated from the pericarp of Garcinia mangostana L. on rat basophilic leukemia RBL-2H3 cell degranulation.
AID435966Percentage EF2K activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771650Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G0 phase at 10 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 3%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417407Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 323-332 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID417404Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 243-250 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID497643Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 30 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID435316Percentage MELK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771647Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 10 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 1%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417395Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 271-289 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512281Inhibition of His-tagged human SAPK4/p38delta expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID771639Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G0 phase at 40 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 3%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID771633Induction of mitochondrial membrane potential loss in human HL60 cells at 20 uM after 24 hrs by rhodamine-123 staining-based FACS flow cytometric analysis (Rvb = 5%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID218564Decrease in inhibition of beta-lactamase due to 10-fold increase in enzyme concentration2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID771642Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G0 phase at 30 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 3%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID1876036Antiviral activity against RABV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435580Percentage Aurora B activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512289Inhibition of human PKBalpha expressed in SF9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID1525155Stability of the compound in CHCl3 under intense heating condition by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID771637Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 40 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 45%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435597Percentage DYRK1A activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512279Inhibition of His-tagged human SAPK2b/p38b2 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID417403Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 132-146 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771631Induction of mitochondrial membrane potential loss in human HL60 cells at 40 uM after 24 hrs by rhodamine-123 staining-based FACS flow cytometric analysis (Rvb = 5%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID771632Induction of mitochondrial membrane potential loss in human HL60 cells at 30 uM after 24 hrs by rhodamine-123 staining-based FACS flow cytometric analysis (Rvb = 5%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417398Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 336-350 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID275971Inhibition of 10 nM AmpC beta lactamase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Interpreting steep dose-response curves in early inhibitor discovery.
AID435480Percentage MSK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1591939Antibacterial activity against Shigella flexneri by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID771644Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 20 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 54%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID634898Inhibition of RhoA activation in human HepG2 cells assessed as decrease of membrane-associated protein level at 10 uM after 24 hrs by Western blot analysis2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Induction of cell cycle arrest by the carbazole alkaloid Clauszoline-I from Clausena vestita D. D. Tao via inhibition of the PKCδ phosphorylation.
AID1525150Stability of the compound in acetone under room temperature by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID435812Percentage PIM1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417389Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 336-350 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771626Induction of apoptosis in human HL60 cells assessed as shrinkage of cell size at 20 to 40 uM after 24 hrs by fluorescence microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435313Percentage CHK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771645Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 20 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 45%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID512275Inhibition of rabbit MKK1 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID1525143Drug metabolism in DMSO-d6 assessed as 6-(3-Acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5-hydroxy-2,2-dimethyl-8-phenyl-8,9-dihydro-2H,10H-pyrano[2,3-f]-chromen-10-one formation measured after 2 months at room temperature by RP-HPLC analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID771652Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID495065Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID771638Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 30 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 1%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID771625Induction of apoptosis in human HL60 cells assessed as nuclear condensation at 20 to 40 uM after 24 hrs by fluorescence microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417390Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 8-18 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512287Inhibition of His-tagged human PKCalpha expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID275970Inhibition of 1 nM AmpC beta lactamase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Interpreting steep dose-response curves in early inhibitor discovery.
AID771649Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 10 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 45%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID52462Inhibitory activity against Chymotrypsinogen from Thermus flavus2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID435416Percentage PAK4 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1525146Drug metabolism in DMSO-d6 assessed as isorottlerin formation measured after 2 hrs at 100 degC by 1H NMR analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID417386Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 271-289 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771634Induction of mitochondrial membrane potential loss in human HL60 cells at 10 uM after 24 hrs by rhodamine-123 staining-based FACS flow cytometric analysis (Rvb = 5%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID512295Inhibition of His-tagged human CK2 expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID416746Inhibition of Escherichia coli AmpC assessed as induction of protein unfolding measured by trypsin mediated degradation of compound-AmpC enzyme complex at 100 uM after 4 hrs by gel electrophoresis2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID497663Inhibition of mouse prion protein (89-230) assessed as assessed as inhibition of fiber formation at 50 uM by transmission electron microscopy2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID435963Percentage CK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435977Percentage MNK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1525144Drug metabolism in DMSO-d6 assessed as isorottlerin formation measured after 2 months at room temperature by HSQC analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID1525147Drug metabolism in DMSO-d6 assessed as 6-(3-Acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5-hydroxy-2,2-dimethyl-8-phenyl-8,9-dihydro-2H,10H-pyrano[2,3-f]-chromen-10-one formation measured after 2 hrs at 100 degC by 1H NMR analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1902441Inhibition of PKCdelta (unknown origin) by IMAP kinase assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
AID1525148Stability of the compound in MeCN under room temperature by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID435172Percentage PAK6 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435993Percentage Src activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771648Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 10 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 54%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID771643Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 20 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 1%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID512297Inhibition of His-tagged human LCK expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID417391Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 42-56 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1525145Drug metabolism in DMSO-d6 assessed as 6-(3-Acetyl-2,4,6-trihydroxy-5-methylbenzyl)-5-hydroxy-2,2-dimethyl-8-phenyl-8,9-dihydro-2H,10H-pyrano[2,3-f]-chromen-10-one formation measured after 2 months at room temperature by HSQC analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID436067Percentage CaMKKbeta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1510611Drug metabolism in DMSO-d6/potassium phosphate buffer assessed as drug recovery with small amount of metabolite formation by 1H-NMR analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID435840Percentage AMPK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID495066Inhibition of anisomycin-induced p38 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID417381Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 8-18 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID218679Inhibition of beta-lactamase from Escherichia coli2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID1591938Antibacterial activity against Escherichia coli by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID435376Percentage RSK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435682Percentage PIM3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512461Inhibition of His-tagged human MAPKAPK2 expressed in Escherichia coli at 10 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435973Percentage MARK3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417380Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 42-56 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512292Inhibition of His-tagged human GSK3b expressed in Sf21 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID771636Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 40 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 54%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435994Percentage SRPK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417415Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 271-289 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1510605Inhibition of alpha-chymotrypsin in bovine pancreas using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID435455Percentage CDK2-cyclinA activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435476Percentage MNK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435705Percentage BRSK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417394Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 132-146 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID497661Inhibition of mouse prion protein (89-230) assessed as assessed as coating of prion protein with colonial particles at 50 uM by transmission electron microscopy2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID1591934Antibacterial activity against Bacillus cereus by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID417413Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 132-146 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512284Inhibition of His-tagged human MSK1 expressed in Sf9 cells at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID436085Percentage HIPK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512291Inhibition of His-tagged human S6K1 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID1525141Stability of the compound in DMSO-d6 measured after 2 months at room temperature by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID435628Percentage ROCK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435876Percentage PRAK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1891067Inhibition of RUVBL1 (unknown origin)
AID771646Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G0 phase at 20 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 3%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID1510608Inhibition of Enterobacter cloacae beta-lactamase treated with enzyme for 10 mins following enzyme incubation with 0.7 to 2.1 M DMSO for 5 mins followed by nitrocefin substrate challenge and measured for 5 mins by DMSO perturbation assay2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID435859Percentage JNK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1525154Stability of the compound in acetone under intense heating condition by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID435967Percentage ERK8 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435173Percentage PDK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435129Percentage PKD1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1315765Inhibition of human USP1/UAF1 complex using Ub-Rho as substrate by qHTS assay2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID435494Percentage PRK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID417411Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 105-128 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1525156Antibacterial activity against Staphylococcus aureus measured after 24 hrs2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID163518Inhibition of Protein kinase C delta (PKCdelta)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID512276Inhibition of His-tagged human MAPK2/ERK2 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435668Percentage PAK5 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID127098Inhibition of p38-regulated activated kinase (PRAK)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID417402Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 109-128 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435119Percentage MKK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512277Inhibition of His-tagged human JNK1a1/SAPK1c expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID275972Inhibition of 20 nM AmpC beta lactamase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Interpreting steep dose-response curves in early inhibitor discovery.
AID417384Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 132-146 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435884Percentage SmMLCK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435367Percentage NEK6 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417393Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 109-128 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID417388Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 323-332 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID417399Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 8-18 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID436080Percentage ERK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512280Inhibition of His-tagged human SAPK3/p38gamma expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID1591935Antibacterial activity against Staphylococcus aureus by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID417397Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 323-332 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1591931Antibacterial activity against Micrococcus luteus by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID771635Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 40 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 1%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID1591933Antibacterial activity against Staphylococcus epidermidis by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID417406Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 291-322 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771629Induction of apoptosis in human HL60 cells assessed as blebbing of cell wall at 10 to 40 uM after 24 hrs by phase contrast microscopic analysis2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435603Percentage HIPK3 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID771641Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 30 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 45%)2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID435426Percentage PKBalpha activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512282Inhibition of MAPKAPK1b from rabbit skeletal muscle at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID436028Percentage PHK activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1525151Stability of the compound in CHCl3 under room temperature by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID634897Inhibition of PKCdelta phosphorylation at Ser643 in human HepG2 cells at 10 uM after 1 hr by Western blot analysis2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Induction of cell cycle arrest by the carbazole alkaloid Clauszoline-I from Clausena vestita D. D. Tao via inhibition of the PKCδ phosphorylation.
AID512298Inhibition of His-tagged human CHK1 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID436038Percentage PIM2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417416Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 291-322 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435459Percentage CK1delta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID512460Inhibition of His-tagged human PRAK expressed in Sf9 cells2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435622Percentage p38delta activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1525152Stability of the compound in MeCN under intense heating condition by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID435241Percentage Lck activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1846605Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 4 days by MTS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219AAA ATPases as therapeutic targets: Structure, functions, and small-molecule inhibitors.
AID435113Percentage MAPKAPK2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1510604Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of Triton X-100 by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1525153Stability of the compound in toluene under intense heating condition by 1H NMR-spectroscopic analysis2019Journal of natural products, 05-24, Volume: 82, Issue:5
The Mosaic of Rottlerin: The Sequel.
AID417383Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 109-128 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID512278Inhibition of His-tagged human SAPK2a/p38 expressed in Escherichia coli at 20 uM2000The Biochemical journal, Oct-01, Volume: 351, Issue:Pt 1
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
AID435218Percentage CaMKKalpha activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1591936Antibacterial activity against Salmonella typhimurium by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID1846606Anticancer activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 4 days by MTS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219AAA ATPases as therapeutic targets: Structure, functions, and small-molecule inhibitors.
AID1591932Antibacterial activity against Streptococcus mutans by CLSI guideline based broth microdilution method2019Journal of natural products, 08-23, Volume: 82, Issue:8
Mallopenins A-E, Antibacterial Phenolic Derivatives from the Fruits of
AID417396Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 291-322 amino acid sequence after 1 hr by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID435631Percentage RSK1 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417405Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 271-289 amino acid sequence after 8 hrs by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID771653Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity.
AID417382Aggregation based inhibition of Escherichia coli AmpC assessed as increase in deuteration of AmpC peptide fragment spanning 105-128 amino acid sequence after 10 mins by hydrogen-deuterium exchange mass spectrometry relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1876210Cytotoxicity against golden hamster BSR cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435121Percentage MST2 activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436064Percentage Aurora C activity remaining in the presence of 10uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID417412Aggregation based inhibition of Escherichia coli AmpC assessed as solvent accessibility of AmpC peptide fragment spanning 109-128 amino acid sequence by measuring ratio of side chain surface area to random coil values per amino acid reside by hydrogen-deu2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Promiscuous aggregate-based inhibitors promote enzyme unfolding.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1799534BP Incorporation Assay from Article 10.1016/j.chembiol.2008.07.015: \\Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.\\2008Chemistry & biology, Sep-22, Volume: 15, Issue:9
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)2006The Journal of pharmacology and experimental therapeutics, Nov, Volume: 319, Issue:2
Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (544)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (0.55)18.7374
1990's16 (2.94)18.2507
2000's296 (54.41)29.6817
2010's199 (36.58)24.3611
2020's30 (5.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.56 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index5.90 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews9 (1.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other546 (98.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]